Chiusura precedente | 2,8500 |
Aperto | 2,8500 |
Denaro | 0,0000 x N/D |
Lettera | 0,0000 x N/D |
Min-Max giorno | 2,8500 - 2,9800 |
Intervallo di 52 settimane | 2,8500 - 2,9800 |
Volume | |
Media Volume | N/D |
Capitalizzazione | 1,413B |
Beta (5 anni mensile) | 1,89 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -0,1790 |
Prossima data utili | 27 lug 2022 - 01 ago 2022 |
Rendimento e dividendo (forward) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | N/D |
Conference call begins at 4:30 p.m. Eastern time todayMIAMI, May 09, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2022. Business Highlights Business highlights for the first quarter of 2022 and subsequent weeks include the following: Acquired ModeX Therapeutics, Inc. (ModeX), gains proprietary immunotherapy technology, new executives and Directors. ModeX is a privately held biotechnology company fo
Dr. Elias Zerhouni, ModeX Chairman, former President of Global R&D at Sanofi and former NIH Director, named President and Vice Chairman of OPKODr. Gary Nabel, ModeX President and CEO, former Chief Scientific Officer at Sanofi and founder of NIH’s Vaccine Research Center, joins OPKO as Chief Innovation Officer and a member of OPKO’s Board of DirectorsAlexis Borisy, ModeX Lead Independent Director and a leading biotechnology entrepreneur and investor, joins OPKO’s Board of Directors Transaction to
MIAMI, May 05, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2022 after the close of the U.S. financial markets on Monday, May 9, 2022. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on May 9th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participants